iart-202102110000917520false00009175202021-02-112021-02-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 11, 2021
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
| | | | | | | | |
| Delaware | 0-26224 | 51-0317849 |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
1100 Campus Road
Princeton, NJ 08540
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section12(b) of the Act:
| | | | | | | | |
| Title of Each Class | Trading Symbol | Name of Exchange on Which Registered |
| Common Stock, Par Value $.01 Per Share | IART | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On February 11, 2021, Lloyd W. Howell, Jr., informed Integra LifeSciences Holdings Corporation (the “Company”) of his intention to resign from the Company’s Board of Directors (the “Board”), effective as of February 26, 2021, in order to pursue other professional opportunities. Mr. Howell did not communicate to the Company any disagreement with the Company on any matter relating to its operations, policies or practices in connection with his resignation, nor is the Company aware of any such disagreement. The Company thanks Mr. Howell for his valued service on the Board, including his service as a member of the Audit Committee of the Board (the “Audit Committee”) and of the Finance Committee of the Board (the “Finance Committee”).
Contemporaneous with Mr. Howell’s resignation and effective February 26, 2021, Keith Bradley, a current member of the Company’s Board will be appointed as a member of the Audit Committee and of the Finance Committee.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION |
| | |
| Date: February 12, 2021 | By: | /s/ Carrie Anderson |
| | Carrie Anderson |
| Title: | Executive Vice President, Chief Financial Officer |
| | and Treasurer |
| | |
| | |
| | |